遠東宏信(03360.HK)發行面值總額12億元票據
格隆匯2月14日丨遠東宏信(03360.HK)公告,於2025年2月6日,公司與聯席牽頭經辦人訂立認購協議,以根據該計劃進行提取,並於2025年2月14日發售及發行提取票據,面值總額爲人民幣12億元,提取票據獲豁免遵守證券法項下的登記規定。提取票據以人民幣計值。
根據標準普爾,提取票據預計將被評爲BBB-。提取票據的該評級不構成購買、出售或持有提取票據的推薦,且標準普爾可隨時修訂或撤回該評級。該評級應該獨立於公司其他證券的任何其他評級或公司的評級進行評估。
公司擬將發售的所得款項淨額用作營運資金及一般公司用途。待取得中國相關政府部門的所有必要批準後,所得款項亦可透過公司間貸款轉借予公司於中國境內的子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.